|
1）Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012; 158: 323-35
|
|
|
|
2）Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991; 325: 393-7
|
|
|
|
|
|
3）Matsumoto M, Bennett CL, Isonishi A, et al. Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS One. 2012; 7: e33029
|
|
|
|
|
|
4）Noris M, Remuzzi G. Hemolytic uremic syn-drome. J Am Soc Nephrol. 2005; 16: 1035-50
|
|
|
|
|
|
5）Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998; 339: 1578-84
|
|
|
|
|
|
6）Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339: 1585-94
|
|
|
|
|
|
7）Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003; 14: 520-35
|
|
|
|
|
|
8）Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994; 83: 435-45
|
|
|
|
|
|
9）Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350: 2572-81
|
|
|
|
|
|
10）Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombo-cytopenic purpura. Blood Cells Mol Dis. 2002; 28: 385-91
|
|
|
|
|
|
11）Chemnitz J, Draube A, Scheid C, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002; 71: 105-8
|
|
|
|
|
|
12）Zheng X, Pallera AM, Goodnough LT, et al. Remission of chronic thrombotic thrombo-cytopenic purpura after treatment with cyclo-phosphamide and rituximab. Ann Intern Med. 2003; 138: 105-8
|
|
|
|
|
|
13）Kosugi S, Matsumoto M, Ohtani Y, et al. Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura. Int J Hematol. 2005; 81: 433-6
|
|
|
|
|
14）Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011; 118: 1746-53
|
|
|
|
|
|
15）Froissart A, Buffet M, Veyradier A, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Micro-angiopathies Reference Center. Crit Care Med. 2012; 40: 104-11
|
|
|
|
|
|
16）Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proceeding New York Pathological Society. 1924; 24: 21-4
|
|
|
|
|
|
17）Amorosi EL, Ultmann JE. Thrombotic thrombo-cytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966; 45: 139-59
|
|
|
|
|
|
18）Pereira A, Mazzara R, Monteagudo J, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol. 1995; 70: 319-23
|
|
|
|
|
|
19）Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008; 112: 11-8
|
|
|
|
|
|
20）Fujimura Y, Matsumoto M, Yagi H, et al. Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. Int J Hematol. 2002; 75: 25-34
|
|
|
|
|
|
21）Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008. Intern Med. 2010; 49: 7-15
|
|
|
|
|
22）Matsuyama T, Kuwana M, Matsumoto M, et al. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost. 2009; 102: 371-8
|
|
|
|
|
|
23）Scheiflinger F, Knobl P, Trattner B, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003; 102: 3241-3
|
|
|
|
|
|
24）Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood. 2007; 109: 2815-22
|
|
|
|
|
|
25）Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombo-cytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003; 102: 60-8
|
|
|
|
|
|
26）Zheng XL, Kaufman RM, Goodnough LT, et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004; 103: 4043-9
|
|
|
|
|
|
27）Coppo P, Wolf M, Veyradier A, et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2006; 132: 66-74
|
|
|
|
|
|
28）Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010; 115: 1500-11; quiz 662
|
|
|
|
|
|
29）Matsumoto M, Yagi H, Ishizashi H, et al. The Japanese experience with thrombotic thrombo-cytopenic purpura-hemolytic uremic syndrome. Semin Hematol. 2004; 41: 68-74
|
|
|
|
|
|
30）Kaneko H, Matsumoto M, Okamoto K, et al. Refractory thrombotic thrombocytopenic purpura successfully treated with a combination of rituximab and vincristine. Rinsho Ketsueki. 2007; 48: 144-7
|
|
|
|
|
|
31）Isonishi A, Plaimauer B, Scheiflinger F, et al. Anti-ADAMTS13 inhibitor boosting with plasma exchange in acquired TTP: Characterization of inhibitors and efficient treatment with rituximab. XXIII congress of ISTH 2011 (Kyoto). Abstract P-WE-475. http://www.isth2011.com/prgrm-common/abstracts/html/00742.html 2011
|
|
|
|
|
|
32）Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med. 1995; 122: 569-72
|
|
|
|
|
|
33）Elliott MA, Heit JA, Pruthi RK, et al. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol. 2009; 83: 365-72
|
|
|
|
|
|
34）Tsai HM, Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol. 2003; 70: 183-5
|
|
|
|
|
|
35）Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombo-tic thrombocytopenic purpura: a study of 11 cases. Blood. 2005; 106: 1932-7
|
|
|
|
|
|
36）Kameda T, Dobashi H, Kittaka K, et al. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment. Clin Rheumatol. 2007; 26: 2159-62
|
|
|
|
|
|
37）Tun NM, Villani GM. Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis. J Thromb Thrombolysis. 2012; 34: 347-59
|
|
|
|
|